

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Straub Clinic & Hospital Department of Nuclear Medicine 2. 888 South King Street Honolulu, HI 96813-3009		In accordance with letter dated January 18, 2024, 3. License No.: 53-18126-01 is amended in its entirety to read as follows:	4. Expiration Date: October 31, 2025 5. Docket No.: 030-14529 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Any byproduct material permitted by 10 CFR 31.11 E. Yttrium-90	7. Chemical and/or physical form A. Any B. Any C. Any D. Prepackaged Kits E. Liquid (IDEC Pharmaceuticals, Model Zevalin)	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed C. 1 curie total D. 5 millicuries total E. Not to exceed 2 sources, 110 millicuries total activity	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any use permitted by 10 CFR 35.300. D. For use in in-vitro studies. E. To be used for dose calibration checks and calibrations and quality assurance testing.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 53-18126-01

Amendment No. 34

Docket or Reference No.:
030-14529**CONDITIONS**

10. Licensed material shall be used or stored at the licensee's facilities located at 888 South King Street, (island of Oahu), Honolulu, Hawaii, 96813-3009.
11. The Radiation Safety Officer for this license is Ronald W. Frick, M.S., CHP, DABR.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users, authorized nuclear pharmacists, and/or authorized medical physicists, in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D., D.O., etc.)</u> | <u>Material and Use</u> |
|---|-------------------------------|
| Marc Coel, M.D. | 35.100; 35.200; 35.300; 31.11 |
| Brandon Itagaki, M.D. | 35.100; 35.200 |
| Brandon Kai, M.D. | 35.200 |
| Yang-En Kao, M.D. | 35.100; 35.200; 35.300 |
| Carol Lai, M.D. | 35.200 |
| Shay J. Lee, M.D. | 35.100; 35.200; 35.300 |
| Rayji S. Tsutsui, M.D. | 35.200 |
13. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee, except as specifically authorized.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 53-18126-01

Amendment No. 34

Docket or Reference No.:
030-14529

14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material in the form of unsealed material and foil or plated sources to quantities below the limits specified in 10 CFR 30.72, which require consideration of the need for an emergency plan for responding to a release of licensed material.
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letter with enclosures dated November 27, 2012 (ML12352A137)
- B. Application dated April 6, 2015 (ML15110A473)
- C. Letter dated October 8, 2015 (ML15288A424)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: February 22, 2024By: _____
Roberto J. Torres
Region IV